search
Back to results

Impact of a Satiating Diet in Obese Men With a Low Satiety Phenotype

Primary Purpose

Obesity, Appetite Disorders

Status
Completed
Phase
Not Applicable
Locations
Canada
Study Type
Interventional
Intervention
Satiating diet
Control diet
Sponsored by
Laval University
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional other trial for Obesity focused on measuring Obesity, Satiety quotient, Appetite control, Weight loss, Satiety phenotype, Functional food

Eligibility Criteria

30 Years - 50 Years (Adult)MaleAccepts Healthy Volunteers

Inclusion Criteria:

  • aged between 30 and 50 years
  • obese (BMI between 30 and 40 kg/m2)
  • overall good health

Exclusion Criteria:

  • Participants taking medication which could influence appetite sensations (hormones, tranquillizers such as chlorpromazine and benzodiazepin, lithium carbonate for bipolar disorders, cyproheptadine, antihistaminic, serotonin antagonist, sulfonylurea and glucocorticoids)
  • Type 2 diabetic patients treated with insulin
  • Large body weight fluctuations (>4 kg over the last two months)
  • High level of restraint behaviour (score > 10 as measured with the Three Factor Eating Questionnaire)
  • Performing more than 3 x 30 minutes/week of physical activity.

Sites / Locations

  • Laval University
  • Laval Hospital

Arms of the Study

Arm 1

Arm 2

Arm 3

Arm 4

Arm Type

Experimental

Experimental

Active Comparator

Active Comparator

Arm Label

Satiating diet-Low satiety phenotype

Satiating diet-High satiety phenotype

Control diet-Low satiety phenotype

Control diet-High satiety phenotype

Arm Description

Low satiety phenotype subjects who were submitted to the experimental diet (satiating diet) for a 16-week period.

High satiety phenotype subjects who were submitted to the experimental diet (satiating diet) for a 16-week period.

Low satiety phenotype subjects who were submitted to the control diet (based on the Canadian Food Guide) for a 16-week period.

High satiety phenotype subjects who were submitted to the control diet (based on the Canadian Food Guide) for a 16-week period.

Outcomes

Primary Outcome Measures

Change from baseline body weight at 16 weeks
Body weight (kg)
Change from baseline satiety responsiveness (satiety quotients) at 16 weeks
Measured by a standardized breakfast test meal using visual analogue scales for 4 appetite sensations (hunger, desire to eat, fullness and prospective food consumption) (mm/100kcal)

Secondary Outcome Measures

Change from baseline BMI at 16 weeks
kg/m2
Change from baseline waist circumference at 16 weeks
cm
Change from baseline resting blood pressure at 16 weeks
mmHg
Change from baseline resting heart rate at 16 weeks
beat/min
Change from baseline resting energy expenditure at 16 weeks
kcal/day
Change from baseline fat mass at 16 weeks
kg
Change from baseline lean body mass at 16 weeks
kg
Change from baseline percent fat mass at 16 weeks
percent (%)
Change from baseline spontaneous energy intake at 16 weeks
Measured following an ad-libitum buffet-type meal (kcal)
Change from baseline daily energy intake at 16 weeks
Three-day dietary record (kcal/day)
Change from baseline diet quality (macronutrient composition) at 16 weeks
Three-day dietary record (% carbohydrates, proteins and lipids)
Change from baseline appetite sensations at 16 weeks (desire to eat, fullness, hunger and prospective food consumption)
Measured following an ad-libitum buffet-type meal (0-150 mm).
Change from baseline binge eating tendencies at 16 weeks
Binge Eating Scale (possible score between 0-46)
Change from baseline distress-related body esteem at 16 weeks
Body Esteem Scale (possible score between 0-92)
Change from baseline cognitive restraint at 16 weeks
Three Factor Eating Questionnaire (possible score between 0-21)
Change from baseline flexible restraint at 16 weeks
Three Factor Eating Questionnaire (possible score between 0-7)
Change from baseline rigid restraint at 16 weeks
Three Factor Eating Questionnaire (possible score between 0-7)
Change from baseline disinhibition at 16 weeks
Three Factor Eating Questionnaire (possible score between 0-16)
Change from baseline susceptibility for hunger at 16 weeks
Three Factor Eating Questionnaire (possible score between 0-14)
Change from baseline depression symptoms at 16 weeks
Beck Depression Inventory (possible score between 0-63)
Change from baseline anxiety symptoms at 16 weeks
State-Trait Anxiety Inventory (possible score between 20-80)
Change from baseline level of stress at 16 weeks
Perceived Stress Scale (possible score between 0-40)
Change from baseline sleeping quality at 16 weeks
Pittsburgh Sleep Quality (possible score between 0-21)
Change from baseline fasting blood glucose at 16 weeks
mmol/L
Change from baseline fasting blood insulin at 16 weeks
mmol/L
Change from baseline fasting blood leptin at 16 weeks
ng/ml
Change from baseline fasting blood cortisol at 16 weeks
nmol/L
Change from baseline fasting blood total cholesterol at 16 weeks
mmol/L
Change from baseline fasting blood HDL-cholesterol at 16 weeks
mmol/L
Change from baseline fasting blood LDL-cholesterol at 16 weeks
mmol/L
Change from baseline fasting blood phospholipids at 16 weeks
mmol/L
Change from baseline fasting blood triglycerides at 16 weeks
mmol/L
Change from baseline fasting blood LDL-apolipoprotein at 16 weeks
mmol/L
Change from baseline fasting blood free T4 at 16 weeks
nmol/L
Change from baseline fasting blood total T3 at 16 weeks
nmol/L
Change from baseline awakening cortisol response at 16 weeks (T0)
Determined from salivary samples taken at the time of awakening (ug/dl)
Change from baseline awakening cortisol response at 16 weeks (T15min)
Determined from salivary samples taken 15 minutes after the awakening (ug/dl)
Change from baseline awakening cortisol response at 16 weeks (T30min)
Determined from salivary samples taken 30 minutes after the awakening (ug/dl)
Change from baseline awakening cortisol response at 16 weeks (T60min)
Determined from salivary samples taken 60 minutes after the awakening (ug/dl)

Full Information

First Posted
April 13, 2017
Last Updated
April 25, 2017
Sponsor
Laval University
Collaborators
Canadian Institutes of Health Research (CIHR)
search

1. Study Identification

Unique Protocol Identification Number
NCT03128697
Brief Title
Impact of a Satiating Diet in Obese Men With a Low Satiety Phenotype
Official Title
Clinical Evaluation to Improve Obesity Intervention Prescription: Functional Foods as a Potential Solution for Individuals With a Low Satiety Quotient Phenotype?
Study Type
Interventional

2. Study Status

Record Verification Date
April 2017
Overall Recruitment Status
Completed
Study Start Date
October 1, 2004 (Actual)
Primary Completion Date
September 30, 2008 (Actual)
Study Completion Date
September 30, 2008 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
Laval University
Collaborators
Canadian Institutes of Health Research (CIHR)

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
No

5. Study Description

Brief Summary
The global research project was organized as a clinical process starting with an evaluation aiming at the determination of a diagnosis pertaining to the degree of satiety signal capacity. It was extended by a phase of metabolic and behavioural characterization to better understand the clinical condition of the patients. The main part of the program was a weight loss intervention that was focused on high satiating foods. Finally, the process was completed by an evaluation allowing to determine the impact of the intervention on the metabolic and behavioural conditions of the patients.
Detailed Description
Dietary restriction, being prescribed as low and very low calorie diets, has been largely used as a strategy of dietary management of obesity. Beyond the fact that these diets fully respect the first law of thermodynamics, they are also rather easy to supervise and they offer a guarantee of substantial weight loss to compliant patients. Dietary restriction strategies also carry important limitations which include their failure to take into account appetite sensations of the obese patient. This point is important since it dictates the extent to which the patient can tolerate his/her dietary regimen without hunger over time as well as its related body weight loss. In this regard, experimental and clinical data show that weight regain up to initial body weight and even more occurs over years after a diet-induced weight loss. Moreover, evidence also revealed that restraint behaviour is difficult to maintain over time and that a decrease in this behaviour is related to weight gain on a long term basis. The challenge thus becomes the search of a strategy that can promote a substantial spontaneous energy deficit without significantly altering hunger and satiety levels as well as their related well-being. Up to now, the only approach which emerges as having the potential to respect these two criteria is the design of functional foods, i.e. foods with sufficient satiety-promoting properties to compensate for the enhancing effect of body fat loss on appetite. The food specialists can rely on a catalogue of functional ingredients that can be used to prepare functional menus in order to improve the regulation of energy balance and body weight stability in individuals prone to obesity. As described above, this issue would be particularly relevant for obese individuals displaying a low satiety phenotype, i.e. individuals experiencing difficulty to match energy intake to expenditure in a context promoting excess food intake. The objectives of this study were to characterize obese men displaying the low satiety phenotype (metabolic and behavioral characteristics) and to determine the impact of highly satiating foods on body weight loss, satiety feelings and compliance in this population. EXPERIMENTAL DESIGN Recruitment of subjects and satiety phenotype determination Each patient referred by a physician was contacted by phone and a first screening interview was performed to validate the inclusion criteria. After recruitment, every subject was met to read and sign the letter of consent as well as to discuss every aspect of the program about which he might have some questions. We took advantage of this brief meeting to measure height, body weight and waist circumference to determine BMI and to estimate the level of abdominal fat. This phase also included a 2-hour session of evaluation in order to determine satiety signal capacity (SQ). At the end of this session, each subject completed the Three-Factor Eating Questionnaire with the specific preoccupation to measure cognitive dietary restraint as an exclusion criterion. The information collected in this first phase of testing was used to subsequently classify subjects on the basis of their satiety signal capacity (low SQ vs normal/high SQ). Subjects not selected to participate in the next phase of the project received, in addition to their health report, a free dietary consultation focusing on the adoption of healthy behaviours. This first phase of testing allowed to rank order subjects on the basis of their score obtained with the satiety quotient. Seventy participants were selected to participate in the study Initial metabolic and behavioural characterization (Time 0) This phase of testing began by a standard medical examination performed by the physician of our research team several days before the main testing session. This permitted to identify potential illnesses influencing appetite control and to evaluate the general health condition of each subject. In order to evaluate the reproducibility over time of the satiety quotient determination and to ascertain the status of subjects determined at the initial evaluation, the standardized breakfast test meal was repeated. However, this test was performed in a session of longer duration that allowed to characterize metabolic and behavioural factors associated with a low/high satiety capacity. The measurements included in this phase of testing were used as baseline measurements for the next phase of this project. Intervention study The 70 participants were randomly assigned to either a weight loss program consisting of a highly satiating diet (n=35) (low to moderate in fat (30-35%), high in fibres (> 25g/day), high protein (20-25% of total energy intake) and including 45-50% energy as carbohydrate mainly provided by foods with low glycemic index and adequate to slightly increased vitamin and mineral intakes) which is expected to induce a spontaneous energy deficit or a diet supervision based on the guidelines concordant with the Canadian Food Guide (n=35) (10-15, 55-60 and 30% energy as protein, carbohydrate, and lipid, respectively). For statistical analysis, 4 subgroups have been created based on the SQ classification: 1) low SQ, high satiating diet 2) low SQ, conventional healthy diet, 3) normal/high SQ, high satiating diet, 4) normal/high SQ, conventional healthy diet. This experimental environment thus corresponded to a two by two factorial design in which the two independent variables are SQ and diet. Participants were encouraged to comply with the diets for a 16-week period even if a resistance to weight loss (i.e weight maintenance during one month) was observed during the protocol. Final metabolic and behavioural characterization (Post-tests; week 16) All the measurements performed at Time 0 were repeated immediately after the 16-week intervention period for each of the four subgroups of subjects. POTENTIAL OUTCOME AND FUTURE PERSPECTIVES The main conceptual outcomes of this were: 1) the characterization of factors implicated in different satiety signal capacities; 2) the investigation of the role of individual capacity of satiety signal in body weight loss and diet compliance, and 3) the determination of the impact of functional menus promoting satiety to compensate for the low spontaneous satiety level in some obese individuals. In addition, this project provided clinical and economical outcomes. Indeed, it represented the first study documenting the weight-reducing impact of a healthy diet based on foods whose functionality have been upgraded by food design. If this project confirms that such a diet can promote weight loss without restriction, but while rather being associated with well-being, this will be a major gain for clinical nutritionists who have up to now unsuccessfully try to counteract the obesity epidemic and who have to deal with consumers who primarily request palatable foods instead of a priori focusing on healthy food. From an economical standpoint, this program will be a reference source of validation for the industry seeking justifications and claims to promote healthy foods facilitating body weight control.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Obesity, Appetite Disorders
Keywords
Obesity, Satiety quotient, Appetite control, Weight loss, Satiety phenotype, Functional food

7. Study Design

Primary Purpose
Other
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Masking
None (Open Label)
Allocation
Randomized
Enrollment
70 (Actual)

8. Arms, Groups, and Interventions

Arm Title
Satiating diet-Low satiety phenotype
Arm Type
Experimental
Arm Description
Low satiety phenotype subjects who were submitted to the experimental diet (satiating diet) for a 16-week period.
Arm Title
Satiating diet-High satiety phenotype
Arm Type
Experimental
Arm Description
High satiety phenotype subjects who were submitted to the experimental diet (satiating diet) for a 16-week period.
Arm Title
Control diet-Low satiety phenotype
Arm Type
Active Comparator
Arm Description
Low satiety phenotype subjects who were submitted to the control diet (based on the Canadian Food Guide) for a 16-week period.
Arm Title
Control diet-High satiety phenotype
Arm Type
Active Comparator
Arm Description
High satiety phenotype subjects who were submitted to the control diet (based on the Canadian Food Guide) for a 16-week period.
Intervention Type
Behavioral
Intervention Name(s)
Satiating diet
Intervention Type
Behavioral
Intervention Name(s)
Control diet
Primary Outcome Measure Information:
Title
Change from baseline body weight at 16 weeks
Description
Body weight (kg)
Time Frame
Pre (Week 0)- and post-intervention (after 16 weeks)
Title
Change from baseline satiety responsiveness (satiety quotients) at 16 weeks
Description
Measured by a standardized breakfast test meal using visual analogue scales for 4 appetite sensations (hunger, desire to eat, fullness and prospective food consumption) (mm/100kcal)
Time Frame
Pre- and post-intervention (week 0 and 16)
Secondary Outcome Measure Information:
Title
Change from baseline BMI at 16 weeks
Description
kg/m2
Time Frame
Pre- and post-intervention (week 0 and 16)
Title
Change from baseline waist circumference at 16 weeks
Description
cm
Time Frame
Pre- and post-intervention (week 0 and 16)
Title
Change from baseline resting blood pressure at 16 weeks
Description
mmHg
Time Frame
Pre- and post-intervention (week 0 and 16)
Title
Change from baseline resting heart rate at 16 weeks
Description
beat/min
Time Frame
Pre- and post-intervention (week 0 and 16)
Title
Change from baseline resting energy expenditure at 16 weeks
Description
kcal/day
Time Frame
Pre- and post-intervention (week 0 and 16)
Title
Change from baseline fat mass at 16 weeks
Description
kg
Time Frame
Pre- and post-intervention (week 0 and 16)
Title
Change from baseline lean body mass at 16 weeks
Description
kg
Time Frame
Pre- and post-intervention (week 0 and 16)
Title
Change from baseline percent fat mass at 16 weeks
Description
percent (%)
Time Frame
Pre- and post-intervention (week 0 and 16)
Title
Change from baseline spontaneous energy intake at 16 weeks
Description
Measured following an ad-libitum buffet-type meal (kcal)
Time Frame
Pre- and post-intervention (week 0 and 16)
Title
Change from baseline daily energy intake at 16 weeks
Description
Three-day dietary record (kcal/day)
Time Frame
Pre- and post-intervention (week 0 and 16)
Title
Change from baseline diet quality (macronutrient composition) at 16 weeks
Description
Three-day dietary record (% carbohydrates, proteins and lipids)
Time Frame
Pre- and post-intervention (week 0 and 16)
Title
Change from baseline appetite sensations at 16 weeks (desire to eat, fullness, hunger and prospective food consumption)
Description
Measured following an ad-libitum buffet-type meal (0-150 mm).
Time Frame
Pre- and post-intervention (week 0 and 16)
Title
Change from baseline binge eating tendencies at 16 weeks
Description
Binge Eating Scale (possible score between 0-46)
Time Frame
Pre- and post-intervention (week 0 and 16)
Title
Change from baseline distress-related body esteem at 16 weeks
Description
Body Esteem Scale (possible score between 0-92)
Time Frame
Pre- and post-intervention (week 0 and 16)
Title
Change from baseline cognitive restraint at 16 weeks
Description
Three Factor Eating Questionnaire (possible score between 0-21)
Time Frame
Pre- and post-intervention (week 0 and 16)
Title
Change from baseline flexible restraint at 16 weeks
Description
Three Factor Eating Questionnaire (possible score between 0-7)
Time Frame
Pre- and post-intervention (week 0 and 16)
Title
Change from baseline rigid restraint at 16 weeks
Description
Three Factor Eating Questionnaire (possible score between 0-7)
Time Frame
Pre- and post-intervention (week 0 and 16)
Title
Change from baseline disinhibition at 16 weeks
Description
Three Factor Eating Questionnaire (possible score between 0-16)
Time Frame
Pre- and post-intervention (week 0 and 16)
Title
Change from baseline susceptibility for hunger at 16 weeks
Description
Three Factor Eating Questionnaire (possible score between 0-14)
Time Frame
Pre- and post-intervention (week 0 and 16)
Title
Change from baseline depression symptoms at 16 weeks
Description
Beck Depression Inventory (possible score between 0-63)
Time Frame
Pre- and post-intervention (week 0 and 16)
Title
Change from baseline anxiety symptoms at 16 weeks
Description
State-Trait Anxiety Inventory (possible score between 20-80)
Time Frame
Pre- and post-intervention (week 0 and 16)
Title
Change from baseline level of stress at 16 weeks
Description
Perceived Stress Scale (possible score between 0-40)
Time Frame
Pre- and post-intervention (week 0 and 16)
Title
Change from baseline sleeping quality at 16 weeks
Description
Pittsburgh Sleep Quality (possible score between 0-21)
Time Frame
Pre- and post-intervention (week 0 and 16)
Title
Change from baseline fasting blood glucose at 16 weeks
Description
mmol/L
Time Frame
Pre- and post-intervention (week 0 and 16)
Title
Change from baseline fasting blood insulin at 16 weeks
Description
mmol/L
Time Frame
Pre- and post-intervention (week 0 and 16)
Title
Change from baseline fasting blood leptin at 16 weeks
Description
ng/ml
Time Frame
Pre- and post-intervention (week 0 and 16)
Title
Change from baseline fasting blood cortisol at 16 weeks
Description
nmol/L
Time Frame
Pre- and post-intervention (week 0 and 16)
Title
Change from baseline fasting blood total cholesterol at 16 weeks
Description
mmol/L
Time Frame
Pre- and post-intervention (week 0 and 16)
Title
Change from baseline fasting blood HDL-cholesterol at 16 weeks
Description
mmol/L
Time Frame
Pre- and post-intervention (week 0 and 16)
Title
Change from baseline fasting blood LDL-cholesterol at 16 weeks
Description
mmol/L
Time Frame
Pre- and post-intervention (week 0 and 16)
Title
Change from baseline fasting blood phospholipids at 16 weeks
Description
mmol/L
Time Frame
Pre- and post-intervention (week 0 and 16)
Title
Change from baseline fasting blood triglycerides at 16 weeks
Description
mmol/L
Time Frame
Pre- and post-intervention (week 0 and 16)
Title
Change from baseline fasting blood LDL-apolipoprotein at 16 weeks
Description
mmol/L
Time Frame
Pre- and post-intervention (week 0 and 16)
Title
Change from baseline fasting blood free T4 at 16 weeks
Description
nmol/L
Time Frame
Pre- and post-intervention (week 0 and 16)
Title
Change from baseline fasting blood total T3 at 16 weeks
Description
nmol/L
Time Frame
Pre- and post-intervention (week 0 and 16)
Title
Change from baseline awakening cortisol response at 16 weeks (T0)
Description
Determined from salivary samples taken at the time of awakening (ug/dl)
Time Frame
Pre- and post-intervention (week 0 and 16)
Title
Change from baseline awakening cortisol response at 16 weeks (T15min)
Description
Determined from salivary samples taken 15 minutes after the awakening (ug/dl)
Time Frame
Pre- and post-intervention (week 0 and 16)
Title
Change from baseline awakening cortisol response at 16 weeks (T30min)
Description
Determined from salivary samples taken 30 minutes after the awakening (ug/dl)
Time Frame
Pre- and post-intervention (week 0 and 16)
Title
Change from baseline awakening cortisol response at 16 weeks (T60min)
Description
Determined from salivary samples taken 60 minutes after the awakening (ug/dl)
Time Frame
Pre- and post-intervention (week 0 and 16)

10. Eligibility

Sex
Male
Minimum Age & Unit of Time
30 Years
Maximum Age & Unit of Time
50 Years
Accepts Healthy Volunteers
Accepts Healthy Volunteers
Eligibility Criteria
Inclusion Criteria: aged between 30 and 50 years obese (BMI between 30 and 40 kg/m2) overall good health Exclusion Criteria: Participants taking medication which could influence appetite sensations (hormones, tranquillizers such as chlorpromazine and benzodiazepin, lithium carbonate for bipolar disorders, cyproheptadine, antihistaminic, serotonin antagonist, sulfonylurea and glucocorticoids) Type 2 diabetic patients treated with insulin Large body weight fluctuations (>4 kg over the last two months) High level of restraint behaviour (score > 10 as measured with the Three Factor Eating Questionnaire) Performing more than 3 x 30 minutes/week of physical activity.
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Angelo Tremblay, PhD
Organizational Affiliation
Laval University
Official's Role
Principal Investigator
First Name & Middle Initial & Last Name & Degree
Drapeau Vicky, PhD
Organizational Affiliation
Laval University
Official's Role
Study Director
Facility Information:
Facility Name
Laval University
City
Quebec
ZIP/Postal Code
G1V 0A6
Country
Canada
Facility Name
Laval Hospital
City
Quebec
ZIP/Postal Code
G2B 4H4
Country
Canada

12. IPD Sharing Statement

Plan to Share IPD
No
Citations:
PubMed Identifier
23792908
Citation
Drapeau V, Blundell J, Gallant AR, Arguin H, Despres JP, Lamarche B, Tremblay A. Behavioural and metabolic characterisation of the low satiety phenotype. Appetite. 2013 Nov;70:67-72. doi: 10.1016/j.appet.2013.05.022. Epub 2013 Jun 20.
Results Reference
result
PubMed Identifier
25329602
Citation
Filiatrault ML, Chaput JP, Drapeau V, Tremblay A. Eating behavior traits and sleep as determinants of weight loss in overweight and obese adults. Nutr Diabetes. 2014 Oct 20;4(10):e140. doi: 10.1038/nutd.2014.37.
Results Reference
result
PubMed Identifier
24129360
Citation
McNeil J, Drapeau V, Gallant AR, Tremblay A, Doucet E, Chaput JP. Short sleep duration is associated with a lower mean satiety quotient in overweight and obese men. Eur J Clin Nutr. 2013 Dec;67(12):1328-30. doi: 10.1038/ejcn.2013.204. Epub 2013 Oct 16.
Results Reference
result

Learn more about this trial

Impact of a Satiating Diet in Obese Men With a Low Satiety Phenotype

We'll reach out to this number within 24 hrs